CoChat
Sign Up
Cited by 700Bone health and osteoporosis researchBone health and treatmentsMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

Open access
Black, Dennis M, Reid, Ian R, Boonen, Steven, Bucci-Rechtweg, Christina, Cauley, Jane A, Cosman, Felicia, Cummings, Steven R, Hue, Trisha F, Lippuner, Kurt, Lakatos, Peter, Leung, Ping Chung, Man, Zulema, Martinez, Ruvie Lou Maria, Tan, Monique, Ruzycky, Mary Ellen, Su, Guoqin, Eastell, Richard·2012·Journal of Bone and Mineral Research
DOI 10.1002/jbmr.1494PMC PMC3427916
Open this paper in CoChat — free accountOpen PDF

Abstract

Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate long-term effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly–Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebo-controlled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n = 616) or placebo (Z3P3, n = 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference = 1.04%; 95% confidence interval 0.4 to 1.7; p = 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n = 14) versus Z3P3 (n = 30) group (odds ratio = 0.51; p = 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p = 0.26) and stroke (3.1% versus 1.5% in Z3P3; p = 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327). © 2012 American Society for Bone and Mineral Research

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jbmr.1494

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 40 references

Research works printed but not linked: 2

  1. Black, 2004, A 5-year randomized trial of the long-term efficacy and safety of alendronate: the FIT Long-term EXtension (FLEX), J Bone Miner Res., 19
  2. Cosman, 2011, After 3 years of IV zoledronic acid administration, who is at highest risk for subsequent vertebral fractures and who should remain on treatment?, J Bone Miner Res., 26

Cited by

Sorted by citations

Items 401–500 of 699

Related

See all

Metadata

Authors
Black, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., Leung, P. C., Man, Z., Martinez, R. L. M., Tan, M., Ruzycky, M. E., Su, G., & Eastell, R.
Affiliations
  • University of California, San Francisco (US)
  • University of Auckland (NZ)
  • KU Leuven (BE)
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
  • University of Pittsburgh (US)
  • Helen Hayes Hospital (US)
  • California Pacific Medical Center (US)
  • University Hospital of Bern (CH)
  • Semmelweis University (HU)
  • Chinese University of Hong Kong (HK)
  • Centro Médico TIEMPO, Buenos Aires, Argentina
  • University of Sheffield (GB)
Corresponding author
Black, Dennis M
ORCID
Venue
Journal of Bone and Mineral Research
Publisher
Oxford University Press (OUP)
Published
2011-12-08
Volume
27
Issue
2
Pages
243-254
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
DOI
10.1002/jbmr.1494
PMC
PMC3427916
OpenAlex
W2106406207
Cited by
700
References
40
Citations by year
2026: 18 · 2025: 37 · 2024: 29 · 2023: 45 · 2022: 40 · 2021: 58 · 2020: 53 · 2019: 49 · 2018: 48 · 2017: 54 · 2016: 61 · 2015: 62 · 2014: 50 · 2013: 49 · 2012: 35
FWCI
49.40
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Journal of Bone and Mineral Research (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (UL1TR000005)
  • University of California, San Francisco
  • Novartis Pharma
  • National Center for Research Resources (UL1RR024153)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
zoledronic acid, osteoporosis, postmenopausal women, long-term treatment, bone mineral density, femoral neck, vertebral fractures, fracture risk, bone turnover markers, serum creatinine, atrial fibrillation, stroke, hypertension, bisphosphonates, adverse events
MeSH terms
Zoledronic Acid, Aged, Diphosphonates, Female, Follow-Up Studies, Humans, Imidazoles, Osteoporosis, Peptide Fragments, Procollagen, Time Factors, Biomarkers, Bone Density, Incidence, Bone Remodeling, Treatment Outcome, Bone Density Conservation Agents, Osteoporotic Fractures

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review